Author pages are created from data sourced from our academic publisher partnerships and public sources.
TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer.
The discovery of a targeted therapeutic compound along with its companion predictive biomarker is a major goal of clinical development for a personalized anticancer therapy to date. Here we present… Expand
TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice
Objective To assess a new adenovirus-based immunotherapy as a novel treatment approach to chronic hepatitis B (CHB). Methods TG1050 is a non-replicative adenovirus serotype 5 encoding a unique large… Expand
Comparative analysis of immunization schedules using a novel adenovirus-based immunotherapeutic targeting hepatitis B in naïve and tolerant mouse models.
Development of active targeted immunotherapeutics is a rapid developing field in the arena of chronic infectious diseases. The question of repeated, closely spaced administration of… Expand
130 A MULTIVALENT ADENOVIRUS-BASED IMMUNOTHERAPEUTIC FOR TREATMENT OF CHRONIC HEPATITIS B INDUCES BROAD, ROBUST AND POLYFUNCTIONAL T CELLS IN NAIVE AND HBV TOLERANT MICE
O031 : TG1050, a novel immunotherapeutic to treat chronic hepatitis B, can control HBsAg and provoke HBsAg seroconversion in HBV-persistent mouse models
Methods: We infected mice with a hepatotropic virus and challenged these mice by injecting TNF. Using knockout mice, as well as biochemical and multiparametric histological methods we analyzed the… Expand
INFORMATION AND CONSULTATION IN THE FIELD OF SOCIAL HOUSING IN FRANCE
TG1050, a novel immunotherapeutic for the treatment of chronic hepatitis B, can control HBsAg and provoke HBsAg seroconversion in HBV-persistent mouse models
s / Journal of Clinical Virology 69 (2015) 223–246 227 evaluated with serial dilutions (106–100 IU/mL; Roche). The quantitative correlation and lower limit of detection were evaluated by use of… Expand
449 TOWARDS THE DEVELOPMENT OF A THERAPEUTIC VACCINE TO TREAT CHRONIC HBV INFECTION: AD5-BASED VACCINES ENCODING MULTIPLE HBV ANTIGENS INDUCE STRONG T-CELL RESPONSES IN PRE-CLINICAL MODELS
P =0.0049; A vs C P < 0.0001; B vs C P =0.0001). Forty seven percent of patients in group A and B were HLA-A2 positive. Tim-3/PD-1 HBV-specific CD8 T cells were 61.95% (median, range 18.7%-95.5%),… Expand
35 TLR3 expressed by melanoma cells contributes to double-stranded RNA anti-tumoral effects in vivo
Glycolipid Antigen Expression in Human Lung Cancer 1
Several mouse monoclonal antibodies which recognize carbohydrate sequences distinguish between different types of human lung cancer immunohistologically. These antibodies bind to glycolipid antigens… Expand